Clinical Trials Directory

Trials / Completed

CompletedNCT02980926

Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty

Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty, a Randomized Controlled Clinical Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Henry Ford Health System · Academic / Other
Sex
All
Age
40 Years – 90 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine if a shorter-acting spinal anesthetic called mepivacaine has advantages over a longer-acting medication called bupivacaine.

Detailed description

Different medications last for different amounts of time and can be changed depending on the length of the procedure. A short acting spinal is generally used for procedures lasting less than 90 minutes. A longer acting medication would be any that lasts longer than 90 minutes. These medications not only block the signals that travel along the pain nerves, they also prevent the signals that tell the patients muscles to move. This means that after a total knee replacement a patient may delayed in their ability to get up and start walking early after surgery. Walking early in the recovery has been shown to decrease the rate of pulmonary embolism and death. Ambulating early is also important to prevent loss of strength, constipation, pneumonia and urinary retention.

Conditions

Interventions

TypeNameDescription
DRUGMepivacaineThis is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
DRUGBupivacaineThis is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.

Timeline

Start date
2016-12-01
Primary completion
2017-03-01
Completion
2017-03-01
First posted
2016-12-02
Last updated
2017-03-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02980926. Inclusion in this directory is not an endorsement.